William Gradishar MD

Oncology•Chicago, IL

Breast Cancer, Hematologic Oncology

Betsy Bramsen Professorship of Breast Oncology, Northwestern University Medical School

Join to View Full Profile

675 N Saint Clair St# GalterChicago, IL 60611
Phone+1 312-695-0990
Fax+1 312-695-1106

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1986 - 1989
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1982 - 1986
University of Illinois College of MedicineClass of 1982

Certifications & Licensure

IL State Medical License 1983 - 2026
FL State Medical License 2013 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Chicago Magazine: Top Doctors Castle Connolly, 2006, 2008, 2010, 2012, 2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Fellow (FASCO) American Society of Clinical Oncologists, 2008
Fellow (FACP) American College of Physicians, 1996
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer Start of enrollment: 1998 Jul 13
Completed
Phase 2
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer Start of enrollment: 1998 Nov 01
Completed
Phase 2
Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 1999 Oct 01
Completed
Phase 2
Fluorouracil-Uracil and Leucovorin in Treating Women With Metastatic Breast Cancer Start of enrollment: 2000 Feb 01
Terminated
Phase 2
Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer Start of enrollment: 1998 Jul 01
Completed
Phase 2
PS-341 in Treating Women With Metastatic Breast Cancer Start of enrollment: 2001 Aug 01
Completed
Phase 2
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer Start of enrollment: 2004 May 01
Completed
Phase 2
In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 1, Phase 2
High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy Start of enrollment: 2004 Mar 01
Terminated
Phase 2
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2006 May 01
Completed
Phase 1
Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies Start of enrollment: 2006 May 01
Terminated
Phase 1
Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 2
Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer Start of enrollment: 2010 Feb 01
Completed
Phase 1
Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy Start of enrollment: 2012 Feb 01
Completed
Phase 1, Phase 2
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Completed
Phase 2
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Start of enrollment: 2014 Sep 09
Terminated
Phase 2
Study of MT-5111 in HER2-positive Solid Tumors Start of enrollment: 2019 Nov 12
Terminated
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi
Nature Communications. 2025-03-06
Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer.
Emily L Podany, Lorenzo Foffano, Lorenzo Gerratana, Arielle J Medford, Katherine Clifton
JAMA Network Open. 2025-02-03
2 citations
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endo...
Lorenzo Gerratana, Andrew A Davis, Lorenzo Foffano, Carolina Reduzzi, Tania Rossi
Cancer Letters. 2025-01-28

Journal Articles

Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer
Denise A Yardley, William J Gradishar, JAMA Oncology
From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing
William J Gradishar, Al B Benson, Massimo Cristofanilli, Allison W Kurian, Value in Health

Lectures

Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Pros and Cons of Extended Adjuvant Endocrine Therapy
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Other

Breast cancer in men
Gradishar WJ
http://www.uptodate.com/contents/breast-cancer-in-men
UpToDate, Wolters Kluwer Health - 2013-02-20
Axillary node metastases with occult primary breast cancer
Gradishar WJ, Kaklamani V
http://www.uptodate.com/contents/axillary-node-metastases-with-occult-primary-breast-cancer
UpToDate, Wolters Kluwer Health - 2012-08-07

Authored Content

From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingAugust 2018

Press Mentions

Greenwich LifeSciences Provides Global Update on FLAMINGO-01April 3rd, 2025
The Evolving Role of Guidelines in Breast Cancer Treatment: 'Guidelines Are Dynamic—They’re Not Meant to Remain the Same'March 8th, 2025
SABCS Session Explores Treatment Considerations in Metastatic ER+ Breast CancerDecember 6th, 2024
Join now to see all